Constitutively Enhanced Lymphatic Pumping in the Upper Limbs of Women Who Later Develop Breast Cancer-Related Lymphedema. by Cintolesi, V et al.
1 
 
Constitutively enhanced lymphatic pumping in the upper limbs of 
women who later develop breast cancer-related lymphedema 
 
Viviana Cintolesi, BSc,1 Anthony WB Stanton, MB BCh, PhD,1 Salena K Bains, MRCS, PhD,2 Emma Cousins, 
BSc,1 A Michael Peters, MD, FRCR, FRCPath, FRCP, MSc,3 Arnie D Purushotham, MD, FRCS,2 J Rodney 
Levick, DSc, DPhil, BM BCh, MA,1 and Peter S Mortimer, MD, FRCP1,4,5 
1Cardiovascular and Cell Sciences Research Institute, St George’s, University of London, London, United 
Kingdom 
2Department of Research Oncology, King’s College London, Guy’s Hospital, London, United Kingdom 
3Department of Nuclear Medicine, Brighton and Sussex University Hospitals NHS Trust, Eastern Road, 
Brighton, United Kingdom 
4Department of Dermatology, St George’s University Hospitals NHS Foundation Trust, Blackshaw Road, 
London, United Kingdom 
5Skin Unit, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, United Kingdom 
 
Name and address for correspondence: 
Professor PS Mortimer 
Cardiovascular and Cell Sciences Research Institute 
St George’s, University of London 
Cranmer Terrace 
London SW17 0RE 
United Kingdom  
2 
 
Abstract 
Background: It has previously been shown that the lymph drainage rate in both upper limbs is greater in 
women destined to develop breast cancer-related lymphedema (BCRL) than in those who do not 
develop BCRL, indicating a constitutive predisposition. We explored constitutive differences further by 
measuring the maximum lymphatic pump pressure (Ppump) and the rate of 99mTc-Nanocoll transport 
generated by the contractile upper limb lymphatics before and after breast cancer surgery in a group of 
women who were followed for 2 years to determine their eventual BCRL or non-BCRL status. 
Methods and Results: Ppump and tracer transport rate were measured by lymphatic congestion 
lymphoscintigraphy in the ipsilateral upper limb in 26 women pre- and post-breast cancer surgery. BCRL 
occurred in 10/26 (38.5%) cases. Ppump in the women who later developed BCRL (40.0 ± 8.2 mmHg) was 
1.7-fold higher than in those who did not develop BCRL (23.1 ± 10.8 mmHg, p = 0.001). Moreover the 
rate of lymph tracer transport into the forearm was 2.2-fold greater in the women who later developed 
BCRL (p = 0.052). Surgery did not significantly reduce Ppump measured 21 weeks post-surgery but 
impaired forearm tracer transport in pre-BCRL women by 58% (p = 0.047), though not in those who did 
not develop BCRL. 
Conclusions: Women destined to develop BCRL have higher pumping pressures and lymph transport, 
indicating harder-working lymphatics prior to cancer treatment. Axillary lymphatic damage from surgery 
appears to compromise lymph drainage in those women constitutively predisposed to higher lymphatic 
pressures and lymph transport. 
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Introduction 
Breast cancer-related lymphedema (BCRL) remains a common sequel to breast cancer 
treatment, the risk of which is increased by obesity, axillary lymph node dissection and radiotherapy to 
the regional lymph nodes.1–4 The pathophysiology of BCRL is complex and the widely held assumption of 
regional lymphatic obstruction to the ipsilateral upper limb following axillary trauma (stopcock 
hypothesis) is an incomplete explanation. Features of BCRL not readily explained by a simple stopcock 
(obstructive) hypothesis include sparing of many breast cancer patients despite extensive axillary lymph 
node surgery; the occurrence of BCRL in patients after only sentinel lymph node biopsy; delayed onset 
of swelling; and non-uniformity of the swelling along the upper limb. Moreover the contralateral upper 
limb does not appear to be normal in women with unilateral BCRL; it exhibits lymphatic capillary 
dilatation in the dermis and greater contralateral hand lymph drainage when there is ipsilateral hand 
swelling.5,6 
A striking recent finding was that women who later develop BCRL have higher lymph drainage 
rates in both upper limbs, in both the muscle (22%–29% higher) and subcutis (22%–50% higher), before 
any swelling is evident, compared with women who do not later develop BCRL.7 The raised lymph 
drainage rates were observed at 7 months post-surgery, so they could have been either a systemic 
effect of the cancer treatment or an inherent, constitutive property. To resolve this point a recent 
prospective study examined breast cancer patients before the cancer surgery. Quantitative 
lymphoscintigraphy was performed before surgery and the patients followed for 13 months post-
surgery. In the 7 out of 38 patients (18%) who developed BCRL, the pre-operative lymph removal rate 
constant k was 16 % higher than in patients who did not later develop BCRL.8 These findings, along with 
those of Stanton et al. and Mellor et al.,5–7 indicate that there are constitutive, pre-operative, bilateral 
differences in lymphatic physiology in BCRL-destined patients. 
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Lymphatic drainage involves active contractile pumping, both in animal models9–12 and human 
limbs.13 To assess lymphatic collector vessel pump function in the upper limbs of women with 
established BCRL, pump function was quantified as the maximum pressure (Ppump) generated in the 
collector lymphatics when lymph flow was blocked by inflating a cuff around the upper arm (lymphatic 
congestion lymphoscintigraphy14). Ppump was found to be significantly impaired in the lymphedematous 
upper limb, by 38% relative to healthy control subjects. Moreover there was a strong negative 
correlation between Ppump and the magnitude of the swelling, i.e., the weaker the pump, the greater the 
swelling. 
To bring together many of the findings reviewed above, we proposed the following working 
hypothesis.15 In pre-BCRL patients the work of lymphatics is already high due to their raised fluid load. 
After axillary surgery, lymphatic pump failure may then develop in a manner analogous to cardiac failure 
following a chronically raised afterload (hypertension). Lymphatic afterload is probably increased 
chronically by axillary lymphatic damage during surgery and radiotherapy, since nodal excision raises 
lymph outflow resistance in sheep.16 The chronically increased work by the lymphatic muscle fibres 
leads eventually to reduced lymphangion contractility, as in hypertensive heart failure; animal studies 
show lymphatic failure at increased distending pressures.10,17,18 The resulting decline in lymph drainage 
rate leads to edema in the drainage territory of the failing lymphatics. The chronic pump failure 
hypothesis offers a rational explanation for the variable delay in onset of BCRL, since a variable period is 
likely to be required for overload failure to reach a critical point. Pump failure can also offer a rational 
explanation for the regionality paradox;15,19 if the constitutionally weakest lymphatic collector vessels 
fail first, swelling will be localised to their drainage territory, i.e., hand, forearm or upper arm. 
In light of the constitutive, pre-operative differences in lymph flow in lymphedema-destined 
breast cancer patients, the question arose as to whether these patients might also have constitutive 
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differences in lymphatic pump function prior to pump failure. The present study evaluates this 
possibility by measuring maximum lymphatic pump pressure Ppump, plus several secondary measures of 
lymphatic transport rate, in the ipsilateral upper limb of women recently diagnosed with breast cancer. 
The study was carried out on the ipsilateral upper limb before and after axillary lymph node surgery, and 
the patients were then followed for 2 years to see who did and did not develop BCRL. 
 
Materials and Methods 
Patients 
Twenty-six women, aged 53 ± 12 (SD) years and newly diagnosed with breast cancer, were recruited 
from the Breast Clinics at St George’s Hospital, London; The Royal Marsden Hospital, Sutton, Surrey; and 
Croydon University Hospital, Croydon, Surrey, UK. The study was approved by the National Research 
Ethics Service Committee (reference 09/H0701/112) and by the Administration of Radioactive 
Substances Advisory Committee (ARSAC) (certificate number 295/3230/25986). Procedures were carried 
out in accordance with the Declaration of Helsinki (2013) of the World Medical Association. All patients 
gave written informed consent. 
Details of the breast cancer and its treatment are summarised in Table 1. Patients underwent 
mastectomy or wide local excision, and axillary lymph node clearance surgery (ANC) or sentinel lymph 
node biopsy (SLNB), as recommended by the multidisciplinary team. All patients received adjuvant 
radiotherapy. Baseline upper limb assessment and lymphatic congestion lymphoscintigraphy (LCL) were 
performed before axillary surgery (the presurgical visit) and repeated 21 ± 15 (SD) weeks after surgery 
(the postsurgical visit). Diagnostic assessment for BCRL (without LCL) was performed at 13.0 ± 2.8 
months and 25.0 ± 4.7 months post-surgery, and also shortly after BCRL onset in the BCRL patients. In 6 
patients the post-surgical LCL was not performed because the patients were unavailable or declined, but 
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these patients were nevertheless followed to see whether or not they developed BCRL. Height was 
measured pre-surgery and weight was recorded on all visits to calculate body mass index (BMI). The 
breast cancer patients who later developed BCRL will be referred to as ‘pre-BCRL’ patients, and the 
patients who did not develop BCRL as ‘non-BCRL’ patients. The ipsilateral upper limb of the pre-BCRL 
patients was the dominant side in 40% of cases and the non-dominant side in 60%; in the non-BCRL 
patients the ipsilateral upper limb was the dominant side in 44% of cases and the non-dominant side in 
56%. 
 
Assessment of the upper limb for lymphedema 
The upper limbs were assessed both by clinical criteria and by volume measurement. The clinical 
features of BCRL are evident at an early, minor stage that is not readily demonstrated by whole-upper 
limb volume measurement, because these volumes can change with change in body mass after cancer 
treatment (see Results). For this reason the diagnosis of BCRL was made clinically, rather than on upper 
limb volumes per se. A Lymphedema Practitioner independently confirmed the diagnosis of BCRL in 
every patient. Clinical assessment was performed as previously described.20 Briefly, BCRL was 
considered to be present if any of the following were detectable: (i) decreased visibility of subcutaneous 
veins on the ventral forearm and dorsal hand; (ii) smoothing or fullness of the medial elbow and distal 
upper arm contours; (iii) increased skin and subcutis thickness if the tissues are pinched between finger 
and thumb; (iv) pitting edema upon application of thumb pressure for 60 s. In addition, the thickness of 
the posterior axillary fold (PAF) was assessed by the ‘pinch test’.21 Patients with ipsilateral PAF 
thickening also had upper limb edema. In addition to the clinical assessment, the volume of each upper 
limb was measured between the ulnar styloid process (wrist) and anterior axillary fold (proximal upper 
arm) using an opto-electronic limb volumeter (Perometer 350S, Pero-System Messgeräte GmbH, 
Wuppertal, Germany).22 
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Lymphatic congestion lymphoscintigraphy (LCL) 
LCL was performed as described,14 with minor changes (below). To check the efficacy of tissue 
compression by the upper arm congestion cuff, preliminary experiments were performed in which 
antecubital venous pressure (Pv) was compared directly with the applied cuff pressure (Pcuff) in the upper 
limb of 6 healthy participants. The participant reclined on a bed with the forearm at heart level. A 
cannula (Venflon 18G) was inserted into the antecubital vein and connected via fine bore tubing 
containing heparinised saline to a calibrated pressure transducer (SensoNor dome transducer and BPM-
832 pressure amplifier; Linton Instrumentation). Pv was displayed on a computer-based data recording 
system (PowerLab 4/30 and LabChart, AD Instruments; PMS Ltd.). A standard blood pressure cuff around 
the upper arm was inflated in a series of steps over the range 22–46 mmHg. Pv increased in parallel with 
the increases in Pcuff, albeit with absolute values 2.9–3.1 mmHg less than Pcuff. These results showed that 
the congesting cuff pressures were transmitted to the deeper tissues with minor attenuation, in 
accordance with the routine use of congesting cuffs to measure arterial blood pressure. 
For the LCL study the patient lay supine on a bed and the brachial artery blood pressure (BP) 
was measured by auscultation from the contralateral upper limb using a mercury sphygmomanometer 
and a Riva-Rocci congestion cuff (AC Cossor & Son Ltd.). For 2 patients with particularly big upper limbs 
the larger, alternative cuff size was used, and the standard size for all others. The cuff was secured 
around the ipsilateral upper arm with the tubing at the top and the cuff bladder centered anteriorly. The 
cuff was wrapped closely and evenly around the limb and the overlap fastened down with adhesive 
tape. The sphygmomanometer was then reattached to the cuff. The upper limb was supported so that 
the forearm was horizontal and at heart level. The gamma camera (Argus Epic; MIC Ltd.) (128 x 128 
matrix, low-energy general purpose collimator) was positioned above the ipsilateral upper limb for 
ventral viewing, with the forearm, upper arm, axilla, and adjacent part of the trunk within the field of 
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view. Patients acclimatised to their surroundings for 45 min, including 20 min whilst lying down before 
the tracer injection and scan. The ambient laboratory temperature was 24.0 ± 0.6 (SD) C (n = 26) on the 
presurgical visit and 23.8 ± 0.6 C (n = 20) postsurgery. Skin temperature, recorded from the ipsilateral 
forearm (YSI 4600 digital thermometer; Henleys Medical Supplies Ltd.), was 29.6 ± 1.3 °C presurgery and 
29.5 ± 1.5 °C postsurgery. 
The cuff was inflated to 60 mmHg (or 50 mmHg if the diastolic BP was < 60 mmHg), using the 
sphygmomanometer. After 2 min of congestion, 50 L of 99mTc-Nanocoll (GE Healthcare) of activity 8.4 ± 
1.6 MBq (n = 26) was injected intradermally between the 2nd and 3rd metacarpal heads of the ipsilateral 
hand, using a microneedle of outer diameter 0.2 mm (Unimed SA). The effective dose was 0.03 mSv. The 
injections were performed consistently and by the same operator throughout, taking on average 52  13 
s (n = 26) to complete. The injected activity was 8.1  1.5 MBq and the duration of the injection was 57  
16 s for the pre-BCRL group, and 8.6  1.6 MBq and 49  11 s for the non-BCRL group (n = 10 and 16, p = 
0.41 and 0.18, unpaired t-tests). Lymphatic density is higher in the dermis than subcutis, so dermal 
injections provide rapid access of the tracer to the upper limb collector lymphatics for gamma-camera 
imaging.23–25 Lymphatic vessels are not readily imaged following intramuscular administration of 
radiotracer in the upper limb.26 99mTc-Nanocoll was used as the lymphatic tracer instead of Technescan 
HIG (human IgG), used formerly,14 because Technescan HIG had been withdrawn from the market by the 
sole manufacturer. Radiochemical purity of the 99mTc-Nanocoll was ≥ 95%. 
Following injection, dynamic imaging was performed at a frame rate of 2.5 min for 70 min. The 
cuff pressure (Pcuff) was held at 60 mmHg for 10 min, a period long enough to demonstrate trapped 
tracer unable to pass beyond the lower border of the cuff. Pcuff was then deflated in 10 mmHg steps 
every 10 min until Pcuff = 0 mmHg. In a further static image acquired after completion of the dynamic 
sequence while the patient remained in position, outline representations of the forearm, cuff and 
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shoulder regions were traced onto the camera face using a 57Co pen marker (High Technology Sources 
Ltd.); the regions thus delineated were used to create templates for the region of interest analysis of the 
dynamic images (see below). The syringe activity was measured before and after injection using the 
gamma camera, to calculate the injected activity. No blood samples were collected. 
 
Measurement of lymphatic function 
Three regions of interest (ROI) were analysed, namely the forearm (ROI1), the subcuff region of the 
upper arm (ROI2), and the axillary-supraclavicular region (ROI3) (Fig. 1). The counts from each 2.5 min 
acquisition were plotted against time for each ROI. At high cuff pressures the tracer was transported 
into the forearm and on towards the lower border of the cuff, but was unable to move more proximally 
because the lymphatic pump was unable to generate sufficient pressure to overcome the cuff pressure. 
As cuff pressure was reduced, there came a point at which lymphatic pressure was high enough to force 
tracer under the cuff and into the axilla. 
Primary measure of lymphatic function, Ppump (mmHg)  Ppump was defined as the Pcuff at which 
radioactivity in ROI3 (axilla) first exceeds the background level (the lymphatic pump pressure).14 
Secondary indices of lymphatic transport  The secondary indices of lymphatic transport, derived using 
fractional counts (local counts divided by injected activity), were (1) the rate of rise of 99mTc-Nanocoll 
activity in ROI1 during the initial 2.5–10.0 min period of trapped lymph (dA/dtROI1, min-1); (2) the 
maximum 99mTc-Nanocoll count in ROI1; and (3) the rate of rise of 99mTc-Nanocoll activity in ROI3 over 
the virtually linear, 20 min segment of the counts-versus-time plot after Ppump exceeded Pcuff (dA/dtROI3, 
min-1). Linear transport occurred at 35–55 min for the pre-BCRL group and 42.5–62.5 min for the non-
BCRL group. All activities were corrected for physical decay of the radionuclide with standardisation to 
time of injection. 
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Statistical analysis 
Results are presented as the mean ± standard deviation (SD) in the text and as the mean ± standard 
error of the mean (SEM) in the tables and figures. The normality of data sets was tested using the 
D’Agostino-Pearson Omnibus test. Student’s paired or unpaired t-test was used to compare differences 
between groups, or the Mann-Whitney test in the case of non-Gaussian distribution (comparison of 
Ppump in the pre-BCRL and non-BCRL groups). The foregoing together with linear regression and two-way 
analysis of variance (ANOVA) were as implemented in GraphPad Prism version 6 (GraphPad Software). 
Differences were considered significant if p ≈ 0.05 or less. 
 
Results 
Clinical, surgical and morphometric data 
Incidence of BCRL and cancer treatment  BCRL was diagnosed clinically in 10/26 women (38.5%), with 
onset at 7 ± 4 months (0–12 months) postsurgery. BCRL developed in 7/14 (50.0%) patients undergoing 
mastectomy, 3/12 (25.0%) patients undergoing wide local excision, 9/20 (45.0%) patients undergoing 
axillary lymph node clearance, and 1/6 (16.7%) undergoing sentinel lymph node biopsy. The number of 
lymph nodes removed in the pre-BCRL group, 16.0 ± 9.3 per patient, was not significantly different from 
non-BCRL, 13.3 ± 10.5 (p = 0.52, unpaired t-test). The number of removed nodes that were positive for 
cancer was again similar in the two groups (4.5 ± 3.5 pre-BCRL versus 3.3 ± 4.2 non-BCRL, p = 0.46). 
Upper limb volumes  Before surgery, both the ipsilateral and contralateral upper limb volumes for the 
pre-BCRL group were greater than for the non-BCRL group, by 22.1% (p = 0.055, unpaired t-test; Table 2) 
and 21.5% respectively (p = 0.054). Surgery had no statistically significant early (i.e., at mean 21 weeks) 
effect on upper limb volume in either the pre-BCRL or non-BCRL group (Table 2; p = 0.31 and 0.48 for 
pre-BCRL ipsilateral and contralateral upper limbs respectively; p = 0.80 and 0.64 for non-BCRL, paired t-
tests). The above analysis hides a significant difference, however; after surgery, ipsilateral volume was 
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significantly greater than contralateral volume in the pre-BCRL patients (p = 0.040), due to small, 
divergent changes; there was a small increase in ipsilateral volume (not itself statistically significant) and 
a small fall in contralateral volume (not itself statistically significant), resulting in a significant difference 
between the upper limbs (Fig. 2). Over 2 years ipsilateral upper limb volume tended to increase with 
time in the pre-BCRL group, as expected, but not in the non-BCRL group or contralateral upper limbs in 
either group. In some cases the increase in ipsilateral upper limb volume was very small, especially at 
the time of diagnosis, emphasising the importance of using clinical criteria to diagnose early BCRL.20 
Body mass index (BMI)  Prior to surgery the pre-BCRL group’s mean BMI (29.5 ± 5.0 kg/m2) was 17% 
higher than that of the non-BCRL group (25.2 ± 3.7 kg/m2) (p = 0.059), in keeping with their 22% greater 
upper limb volumes. Higher BMI is a known risk factor for BCRL;1,27 our data indicate that upper limb 
volume is also a risk factor. BMI did not change significantly up to 25 months postsurgery (p = 0.94 for 
time-points, two-way ANOVA). 
 
Tracer movement along the lymphatic system of the upper limb 
Representative images from a dynamic scan of a pre-BCRL, pre-surgical patient are shown in Figure 1. 
The radiotracer entered the hand and forearm lymphatics rapidly, in some cases while the injection was 
still in progress (< 1 min). After the injection was complete, the tracer traversed the distance from the 
hand depot to the distal border of the cuff (mean distance 30.4 cm) at a velocity of 7.2 ± 4.3 cm/min (n = 
26). Up to 3 (mean 1.6) lymph tracks were imaged in the forearm during pre-surgical LCL and 1–4 (mean 
1.7) tracks during the post-surgical LCL. Dermal rerouting of lymph drainage was not evident in any 
patient, either pre- or postsurgery. Tracer accumulated at the distal border of the congestion cuff until 
the pressure in the cuff was lowered sufficiently to allow tracer to pass under the cuff (ROI2) and into 
the axilla (ROI3). 
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Comparison of lymphatic function in the pre-BCRL and non-BCRL patients before surgery 
Ppump before surgery  Maximum lymphatic pump pressure in the pre-BCRL and non-BCRL groups was 
compared at the pre-surgical time-point in order to test the hypothesis that there is an early, 
constitutive difference in lymphatic pumping in pre-BCRL women. Individual Ppump values are plotted in 
Figure 3. Ppump in the pre-BCRL group (40.0 ± 8.2 mmHg) was on average 73% higher than Ppump in the 
non-BCRL group (23.1 ± 10.8 mmHg, n = 10 and 16; p = 0.0007, Mann-Whitney test). A bimodal 
distribution of Ppump has been reported previously in healthy individuals.14 It is interesting to note that 
when the Ppump values of both pre- and non-BCRL groups are pooled, a bimodal distribution is evident 
(Fig. 3, right array). This raises the possibility that two human populations, with high and low Ppump 
respectively, account for the bimodality in the data of Modi et al.14 
Lymphatic transport dynamics before surgery  There were large differences in the lymphatic transport 
of 99mTc-Nanocoll between the two groups before surgery. These are illustrated in Figure 4A, B, which 
shows the time-courses of activity in each of the three ROIs over the duration of the 70 min scan. 
Several features distinguished the pre-BCRL from the non-BCRL group. (i) The rate of rise of tracer 
activity in ROI1 during the initial trapped lymph phase (2.5–10.0 min), dA/dtROI1, was faster in the pre-
BCRL patients that in the non-BCRL patients. (ii) The peak, accumulated activity in ROI1 during the 
trapped lymph phase was higher in pre-BCRL than non-BCRL patients. (iii) The rate of rise activity in ROI3 
after tracer began to be pumped beyond the cuff, dA/dtROI3, was faster in pre-BCRL than non-BCRL 
patients. Data analysis (Table 3) showed that dA/dtROI1 for pre-BCRL patients was approximately double 
that for non-BCRL patients (p = 0.052) and dA/dtROI3 for pre-BCRL patients was 1.55 times higher than for 
non-BCRL patients (p < 0.0001). All four measures of lymphatic function were thus consistent with a 
more active lymphatic pump in pre-BCRL patients compared with non-BCRL patients. 
 
Comparison of lymphatic function before and soon after surgery 
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Pre-BCRL patients, before versus soon after surgery  The marginal decline in Ppump from 40.0 ± 8.2 
mmHg prior to surgery to 36.7 ± 10.0 mmHg at 21 weeks after surgery was not statistically significant (n 
= 9 pairs, p = 0.50, paired t-test). By contrast, the indices of lymphatic transport in pre-BCRL patients 
were all significantly lower at 21 weeks postsurgery (Fig. 4 A versus C, Fig. 5). During the trapped-lymph 
phase, dA/dtROI1 postsurgery fell to 42% of its presurgery level (p = 0.047, comparison of slopes) and the 
maximum count in ROI1 fell to 51% of the presurgery level (p = 0.025, n = 9, paired t-test). When cuff 
pressure was lower than lymph pressure, dA/dtROI3 post-surgery fell to 27% of the presurgery level (p < 
0.0001, comparison of slopes). 
Non-BCRL patients, before versus soon after surgery   Surgery had much less effect on the lymphatic 
system in non-BCRL patients than in pre-BCRL patients. Ppump was well maintained at 21 weeks after 
surgery in the non-BCRL patients (presurgery 23.1 ± 10.8 mmHg, postsurgery 24.5 ± 11.3 mmHg; n = 11 
pairs, p = 0.78, paired t-test). The two lymphatic transport indices for ROI1 were likewise little changed 
postsurgery (Fig. 4 B versus D, Fig. 5); dA/dtROI1 was not reduced (21% increase not significant, p = 0.56) 
and the maximum count in ROI1 was not reduced (20% increase not significant, p = 0.32, n = 11). 
dA/dtROI3 declined postsurgery, by 28% (p = 0.0008), but this was a relatively small change compared 
with the 73% fall in dA/dtROI3 in the pre-BCRL patients (Fig. 5). 
Comparison of pre-BCRL versus non-BCRL patients soon after surgery   After surgery, Ppump for the pre-
BCRL group (36.7 ± 10.0 mmHg, n = 9) still exceeded that of the non-BCRLs (24.5 ± 11.3 mmHg, n = 11) 
but the difference was smaller than before surgery (12.1 mmHg; p = 0.022, unpaired t-test). Because 
dA/dtROI1 in the pre-BCRL group had been greatly reduced by surgery, it was no longer higher than in the 
non-BCRL group (p = 0.45).  The same was true for peak activity in ROI (p = 0.18). In the case of dA/dtROI3, 
the decrease caused by surgery in the pre-BCRL group was so large that the pre-BCRL value after surgery 
was significantly lower than in the non-BCRL group (p = 0.0003). 
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Discussion 
The primary aim of this study was to test the hypothesis that women destined to develop BCRL 
after breast cancer treatment have constitutive differences in upper limb lymphatic physiology. The 
previous evidence underlying the hypothesis was summarised in the Introduction and included raised 
lymph flows in pre-BCRL women.7,8 The present data, obtained before axillary lymph node surgery or 
radiotherapy, support the hypothesis; the results showed highly significant differences in lymphatic 
pump pressure and lymph tracer transport between those who later developed BCRL and those who did 
not. Moreover the data indicate a more active, not weaker lymphatic system in the pre-BCRL women. By 
contrast, once long-standing lymphedema is present (mean 7.4 years), Ppump is reduced, indicating a 
weakened lymphatic pump.14 The second main finding was that although the breast cancer treatment 
did not cause a significant, early (21 week) fall in lymphatic pump pressure, it did cause striking 
reductions in forearm lymph transport rates in the pre-BCRL patients, with relatively little effect in non-
BCRL patients. Thus, whereas a marked fall in pump pressure is a later event in lymphedema 
development,14 our new results reveal evidence of impaired lymphatic transport rates within 5 months 
of treatment. 
 
Upper limb volumes, incidence of BCRL and risk factors 
We applied strict clinical criteria, developed previously, for the diagnosis of BCRL.20 The diagnosis of 
early, mild BCRL based purely on volume measurement can be confounded by other factors, such as 
weight change, that affect upper limb size.28,29 The incidence of BCRL (38.5%) is within the range 
reported in recent studies; meta-analysis of nine prospective cohort studies gives an incidence of BCRL 
diagnosed by more than one method of 28.2% (mean; range 11.8%–53.5%).1 Nevertheless the question 
arises as to whether 2 years’ follow-up is sufficient; DiSipio et al.1 reported that the incidence of BCRL 
increases up to 2 years after diagnosis or surgery (24 studies), whereas two questionnaire studies 
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reported an increase beyond 2 years.30,31 Paskett et al.30 reported that whereas the estimated 
prevalence (repeated episodes or continuous swelling) was 23%–29% for any assessment interval, the 
incidence of episodic swelling increased beyond 2 years (48% at 2 years, 54% at 3 years). Norman et al.31 
reported an increase in cumulative incidence from 30% at 2 years to 41% at 5 years. Data from objective 
and subjective measures of lymphedema rates can show considerable discordance.27 In the present 
study all cases of BCRL developed within 12 months of surgery and were diagnosed according to strict 
clinical criteria with confirmation by a Lymphedema Practitioner; no cases were diagnosed in the second 
year. 
The study was not designed to identify risk factors for BCRL but nevertheless showed that BCRL 
incidence was 2.7-fold higher in the patients receiving axillary lymph node clearance than SLNB. Axillary 
lymph node clearance surgery is a known risk factor for BCRL.27 The number of lymph nodes removed 
and the number positive for cancer were similar in both the pre-BCRL and non-BCRL groups. Higher BMI 
is an established risk factor for BCRL,1,27 and BMI was 17% higher in the pre-BCRL than the non-BCRL 
group; consistent with this was the 22% greater ipsilateral and contralateral upper limb volumes in the 
pre-BCRL group, indicating that upper limb volume is a related risk factor. It is currently unknown 
whether pre-surgical upper limb volume is an independent risk factor for BCRL. 
 
Constitutively raised lymphatic function in the BCRL-destined group 
The results in Figure 3 showed that collector lymphatics distal to the cuff in pre-BCRL patients were able 
to pump lymph to a higher maximum pressure than those in non-BCRL patients. Moreover the faster 
dA/dtROI1 and higher maximum activity in ROI1 of pre-BCRL patients indicated a more rapid transport of 
lymph from the hand depot into the collector lymphatics of the forearm; and the faster dA/dtROI3 
indicated a more rapid transport of lymph into the axilla after Ppump exceeded Pcuff. These findings 
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combine to support the hypothesis of constitutively enhanced lymphatic function in women destined to 
develop BCRL. 
 
LaPlace’s law and the raised Ppump 
What mechanism(s) might underlie the pre-operative difference in Ppump between the two groups? 
LaPlace’s law states that the pressure P generated by tension T in a thin-walled tube of radius R equals 
T/R. This raises the question of whether the lymphatic smooth muscle contractile force T is greater in 
pre-BCRL than non-BCRL patients, or whether the collector vessel radius R is smaller. Although we have 
no direct evidence on this point, increased lymphatic smooth muscle activity (force and/or frequency of 
contraction) seems the more likely explanation, because the raised dA/dtROI1 and maximum ROI1 activity 
indicate an increased rate of lymph transport (flow) - a finding broadly in keeping with the raised 
lymphatic drainage rate constant k in pre-BCRL patients reported previously.8 
Limited evidence against a smaller vessel radius comes from the observation of wider initial 
lymphatics in the contralateral forearms of women with BCRL when compared with the forearms of non-
BCRL breast cancer patients;5 dilated lymphatic collectors imaged in BCRL limbs (median duration 24 
months) by magnetic resonance lymphangiography,32 and (in early lymphedema) collector vessel ectasia 
observed in histological sections from secondary lymphedema of the leg.33 Studies employing X-ray 
lymphangiography have demonstrated dilated lymphatic collectors in BCRL and also following axillary 
dissection but in the absence of upper limb swelling.34–36 
 
Possible causes of raised Ppump 
Assuming that the high Ppump, along with the other indices, indicates enhanced lymphatic contractile 
force in pre-BCRL patients, what might cause this? A possible factor is the physiological adaptation of 
lymphatic smooth muscle, either by hypertrophy or raised contractility, to the chronically high fluid load 
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(preload) in pre-BCRL patients. A high fluid load is indicated by the raised lymphatic removal rate 
constant k in pre-BCRL patients.7,8 This is supported by the recent report of raised capillary filtration 
capacity in both forearms of BCRL patients relative to the forearms of matched breast cancer patients 
without BCRL,37 although equivalent data from pre-BCRL patients is lacking. Also, the findings were 
based on short (3–4 min) congestions and are contrary to results based on the classic, longer congestion 
method.38 Physiological adaptation of lymphatic smooth muscle to a constitutively high resistance 
axillary node pathway (afterload) is an additional, speculative possibility. In single lymphangions from 
the rat mesentery, in which input and output pressures were controlled, elevated afterload triggered a 
time-dependent increase in lymphatic contractility, modulated by change in preload.18,39 Genetic factors 
have also been related to BCRL susceptibility.40–42 
 
Hypothesis linking raised Ppump in pre-BCRL and subnormal Ppump in established BCRL; potential 
key role of lymphatic collector vessel smooth muscle work 
Not only is Ppump in established BCRL lower than the Ppump of normal, healthy subjects but also the 
severity of the swelling correlates negatively with Ppump indicating that partial failure (weakening) of the 
collector lymphatic pump over the years contributes to the pathogenesis of BCRL.14 The new findings in 
this study raise the question ‘why would women with intrinsically stronger lymphatic pumps than others 
be more prone to pump failure after surgery?’ The high transport rates in the pre-BCRL patients (Fig. 
4A), along with their high lymph flows7,8 offer a rational, albeit speculative explanation, as follows. The 
stroke work of a contracting lymphangion = volume of lymph ejected (V) x active pressure increase 
(P), and the lymphangion work rate = (V/t) x P, i.e., lymph flow x P. The high lymph flow in the pre-
BCRL population thus imposes a chronically high work rate on the lymphatic smooth muscle. We 
propose that this may be close to the maximum chronically sustainable work rate. Surgical removal of 
lymph nodes raises the outflow resistance to lymph in sheep.16 If the same is true in humans (perhaps 
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exacerbated by the radiotherapy), then the previous level of lymph flow can only be maintained by a 
rise in P (afterload), further increasing the work rate (V/t) x P. Over a long period the increased 
work may cause a partial failure of lymphangion force generation (intrinsic smooth muscle failure) 
and/or vessel dilatation; the latter reduces the conversion of wall tension into pressure (LaPlace’s law) 
and may impair lymphatic valve competence. The ‘lymphatic work’ hypothesis has as its analogue the 
chronic failure of a dilated heart resulting from a high preload and raised afterload (hypertension). The 
majority subset of women that avoid BCRL may do so partly because their lymphatic system normally 
operates at a lower preload, leaving them with a greater reserve pump capacity. 
Additional pathogenic factors may also come into play after pump failure, for instance 
degenerative histopathological processes. A recent study described progressive histopathological 
changes in collector lymphatic vessels harvested from patients affected by lower limb lymphedema after 
the surgical removal of lymph nodes for gynaecological cancers.33 With increasing disease progression 
and severity the characteristics of the normal collector lymphatics were lost. In early stage lymphedema 
most lymphatic vessels were normal or showed ectasia, which by LaPlace mechanics will tend to reduce 
pump pressure, even if contractile force were unimpaired. A minority of vessels had a thickened wall 
and narrower lumen. Sclerosis was commoner and ectasia less common with increasing severity of 
lymphedema. Sclerosis of upper limb collector lymphatics would further impair lymphatic pumping and 
worsen the swelling. Severe sclerosis was observed in superficial lymphatics in the upper limb of a 
patient with refractory BCRL of 18 years’ duration.43 Inflammatory triggers for the above might be 
aggravated by the association between obesity and an abnormal inflammatory response, perhaps 
involving macrophage migration.44,45 
 
Impaired lymphatic transport dynamics in pre-BCRL patients following axillary surgery 
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Transport into forearm from hand depot  The slight fall in pre-BCRL Ppump at 4.8 months postsurgery 
was not statistically significant, yet at the same time point the lymphatic transport into the pre-BCRL 
forearm was roughly halved; dA/dtROI1 fell by 58%, maximum ROI1 activity by 48%. The contrast between 
the large fall in hand-to-forearm transport rate and relatively unchanged Ppump could be explained if the 
more distal contractile lymphatics (i.e., between hand depot and forearm) are weaker than proximal 
ones close to the cuff, which were still capable of generating a high Ppump. The data in Figure 4A versus C 
may thus be an early clue that distal lymphatics are the weakest link in the chain and begin to fail before 
more proximal lymphatics. 
Transport into the axillary-supraclavicular region  The fall in dA/dtROI3 after surgery was much more 
pronounced in pre-BCRL (73% reduction) than non-BCRL patients (28% reduction), despite the relatively 
well maintained Ppump in the pre-BCRL group. The interpretation of dA/dtROI3 after surgery is complicated 
by the fact that some lymph nodes have been removed from this ROI. The reduced ROI3 transport in 
both pre-BCRL and non-BCRL groups may be caused partly by increased lymph drainage resistance after 
axillary surgery; and the greater reduction in the pre-BCRL group may be caused by the slowed delivery 
of 99mTc-Nanocoll by the markedly impaired forearm transport vessels (transport in series). Other 
possibilities include more extensive axillary lymphatic trauma from the cancer surgery or radiotherapy,4 
which the study was not designed to explore. 
 
Limitations of present study 
To test further the hypothesis of a constitutively different Ppump in pre-BRL patients, measurements of 
Ppump and transport dynamics in both upper limbs would have been valuable. This was not feasible in 
practice because of the demands it would have placed on the patients shortly before their cancer 
surgery. Ppump data at 2 years, after lymphedema was established, would be useful, to check on the 
decline in function known to occur over several years.14 Many aspects of the proposed working 
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hypothesis remain speculative and call for further work. For example, we are not aware of any 
comparative study of lymphatic smooth muscle structure and function in the distal collectors versus 
proximal collectors of the human upper limb; and apparently only one study (in sheep) has examined 
the effect of node removal on the hydraulic resistance to lymph transport out of a limb. 
 
Conclusions 
A disease model for BCRL emerges from the body of evidence presented in this study. Women destined 
to develop BCRL have constitutively higher lymph loads and higher lymphatic pumping pressures. Breast 
cancer treatment per se has relatively little effect on maximum lymphatic pressure generation initially 
but nevertheless impairs lymph transport in those subsequently developing BCRL. Therefore axillary 
lymphatic obstruction is not the sole explanation for BCRL; surgery appears to compromise lymph 
drainage in those women constitutively predisposed but much less so in those women with 
constitutively lower lymphatic pressures and transport. In women destined to develop BCRL the 
lymphatic contractile work rate is already high and if this is raised further by increased resistance to 
axillary drainage following cancer treatment and/or further increase in lymph load, the lymphatics are 
gradually tipped into chronic failure. This is analogous to high preload and high afterload cardiac failure 
in systemic hypertension. Reduced lymphatic pump activity then leads to overt clinical edema. The 
identification of women belonging to an ‘at-risk’ group, with higher lymphatic preloads prior to cancer 
treatment, would provide an opportunity for pharmacological intervention aimed at lowering preload; 
this could in theory prevent BCRL if introduced early enough. 
 
Authors’ Note 
Follow-up is now at least 3 years since cancer surgery for all patients, and no further cases of BCRL have 
developed. 
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Table 1. Surgical and pathological data for the breast cancer patients. 
             
Patient Age Breast      Axillary No. of LN              Tumor histology 
ID (yr) surgery      surgery removed (+) Grade Type       Size (mm) ER 
             
Pre-BCRL group 
004 69 WLE      SLNB  4 (0)  3 IDC        13  + 
015 42 WLE      ANC  22 (4)  3 IDC        45  – 
019 51 M      ANC  28 (10)  2 IDC, DCIS     43  + 
021a 74 M      ANC  14 (7)  2 IDC, DCIS     160  + 
022 72 M      ANC  17 (7)  3 IDC, DCIS*   43  + 
023a  50 M      ANC  4 (3)  3 IDC, DCIS     35  – 
028 51 WLE      ANC  32 (8)  2 IDC, DCIS     33  + 
030 49 M      ANC  10 (5)  2 IDC, DCIS*   70  + 
031 38 M      ANC  12 (0)  2 IDC, DCIS*   50  + 
039a  52 M      ANC  17 (1)  3 IDC        NR  NR 
Non-BCRL group 
003 37 M      ANC  15 (13)  2, 3 IDC        NR  + 
007a  64 M      ANC  33 (12)  3 IDC        75  + 
010 62 M      ANC  9 (4)  2 IDC        35  + 
017a  50 M      ANC  16 (5)  2 IDC        20  + 
018 43 WLE      SLNB  5 (0)  2 IDC, DCIS     35  + 
020 47 WLE      SLNB  1 (0)  1 IDC        NR  NR 
024 47 WLE      ANC  2 (0)  1 ICC        11  + 
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025 67 WLE      SNLB  1 (0)  2 ILC        11, 15 + 
027 75 WLE      ANC  18 (5)  2 IDC, DCIS     43  + 
029 35 M      ANC  17 (3)  2 IDC        88  + 
032 52 WLE      ANC  31 (3)  3 IDC        22  + 
034 62 WLE      SLNB  3 (0)  2 IDC, ILC        14  + 
035 40 WLE      SLNB  1 (0)  1 IDC, DCIS     35  + 
036 47 M      ANC  19 (1)  3 IDC, DCIS     30  + 
037 42 WLE      ANC  20 (1)  3 IDC        56  – 
038 49 M      ANC  22 (6)  3 IDC        45  + 
             
Pre-BCRL group: the patients who later developed breast cancer-related lymphedema; non-BCRL group: 
the patients who did not develop BCRL. 
ANC, axillary lymph node clearance surgery; DCIS, ductal carcinoma in situ (*high-grade); ER, oestrogen 
receptor status (positive [+], negative [–]); ICC, invasive cribriform carcinoma; IDC, invasive ductal 
carcinoma; ILC, invasive lobular carcinoma; LN, lymph node, with the number positive for cancer in 
brackets; M, mastectomy; NR, not recorded; SLNB, sentinel lymph node biopsy; WLE, wide local 
excision. All patients received adjuvant radiotherapy. 
aDied. 
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Table 2. Ipsilateral and contralateral upper limb volumes in the pre- pre-BCRL patients and the non-BCRL 
patients, before and after axillary surgery. 
             
  Presurgical upper limb volumes (mL) Postsurgical upper limb volumes (mL) 
  Pre-BCRL (10) Non-BCRL (16) p* Pre-BCRL (10) Non-BCRL (11) p* 
             
Ipsilateral 2312 ± 205 1894 ± 103 0.055 2369 ± 226 2007 ± 142 0.18 
Contralateral 2321 ± 192 1910 ± 107 0.054 2227 ± 202 2049 ± 150 0.48 
p**  0.88  0.59   0.040  0.34 
             
Number of patients in each group shown in brackets; values are means ± SEM. In both groups, neither 
the ipsilateral nor the contralateral limb changed significantly in volume by 21 weeks postsurgery. 
p*, comparison of the pre-BCRL and non-BCRL groups (unpaired t-test). p**, comparison of the 
ipsilateral and contralateral upper limbs (paired t-test). BCRL, breast cancer-related lymphedema. 
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Table 3. Summary of measurements of lymphatic function obtained by lymphatic congestion 
lymphoscintigraphy in the pre-BCRL and the non-BCRL patients, before and after axillary surgery. 
             
  Presurgical measurements       Postsurgical measurements 
Pre-BCRL (10) Non-BCRL (16) p      Pre-BCRL (9) Non-BCRL (11) p 
             
Ppump (mmHg) 40.0 ± 2.6 23.1 ± 2.7 0.0007*     36.7 ± 3.3 24.5 ± 3.4 0.022 
dA/dtROI1 (min-1) 2.32 ± 0.30 1.07 ± 0.35 0.052      0.98 ± 0.37 1.30 ± 0.10 0.45 
Peak countROI1 48.6 ± 8.11 33.7 ± 3.73 0.072      25.2 ± 8.62 40.2 ± 7.09 0.18 
dA/dtROI3 (min-1) 0.62 ± 0.02 0.40 ± 0.02 <0.0001     0.17 ± 0.01 0.29 ± 0.02 0.0003 
             
Number of patients in each group shown in brackets; values are means ± SEM. 
Ppump, lymphatic pump pressure; ROI, region of interest; dA/dtROI1, rate of rise of fractional count in ROI1 
(x 103) determined by linear regression analysis of mean fractional counts over 2.5–10.0 min (pre-BCRL 
and non-BCRL, ± SE); dA/dtROI3, rate of rise of fractional count in ROI3 (x 103) by linear regression analysis 
of mean fractional counts over 35–55 min (pre-BCRL) or 42.5–62.5 min (non-BCRL) (± SE); Peak countROI1, 
maximum fractional count in ROI1 (x 103). p, comparisons of the pre-BCRL group with the non-BCRL 
group, before or after surgery (*Mann–Whitney test; comparison of regression slopes for dA/dt; 
unpaired t-test for the other comparisons). See text and Figure 5 for presurgery versus postsurgery 
statistical comparisons. BCRL, breast cancer-related lymphedema.  
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Figure 1. Lymphatic congestion lymphoscintigraphy performed before axillary surgery on the ipsilateral 
upper limb of a patient who later developed breast cancer-related lymphedema. Three regions of 
interest (ROI1 [the lowermost ROI], forearm; ROI2, subcuff; ROI3, axilla) are superimposed and the 
number of minutes elapsed since the injection are shown. (A) 2.5 min, Pcuff = 60 mmHg. The lymphatic 
tracer has traversed the forearm and reached the distal border of the cuff. (B) 10 min, Pcuff = 60 mmHg. 
Activity is unable to pass under the cuff. (C) 27.5 min, Ppump = 40 mmHg. Activity has started to pass 
under the cuff. (D) 30 min, Pcuff = 40 mmHg. Activity has just reached the axilla. Ppump (the cuff pressure 
at which the intra-lymphatic pressure overcame the surrounding occluding pressure, allowing tracer to 
pass into ROI3) = 40 mmHg. (E) 37.5 min, Pcuff = 30 mmHg. Lymph nodes are imaged in the axilla. (F) 60 
min, Pcuff = 0 mmHg. There is prominent nodal activity with tracer persisting in the lymphatics. Images 
from patient 028. 
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Figure 2. Changes in ipsilateral and contralateral upper limb volume following axillary surgery for the 
pre-BCRL and non-BCRL patients relative to their presurgical volumes (= 100%). Means ± SEM, with the 
number of patients shown above each point. The postsurgical measurement was at 21 weeks. BCRL, 
breast cancer-related lymphedema. 
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Figure 3. Lymphatic pump pressures (Ppump) in collector lymphatics of the ipsilateral upper limb in breast 
cancer patients measured before axillary surgery. The 10 pre-BCRL and 16 non-BCRL patients are shown 
separately (left and center arrays). Ppump for the pooled group of the 26 patients (right array) shows a 
bimodal distribution. The horizontal lines indicate the means (40.0, 23.1 and 29.6 mmHg, respectively). 
Ppump was highly significantly greater in the pre-BCRL patients than the non-BCRL patients (p = 0.0007, n 
= 10 and 16, Mann-Whitney test). 
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Figure 4. Radioactive counts recorded from three regions of interest (ROI) in the ipsilateral upper limb 
during lymphatic congestion lymphoscintigraphy and plotted as a fraction of the injected activity (means 
± SEM) against time since injection. ROI1, forearm; ROI2, subcuff; ROI3, axilla. The cuff pressure (Pcuff) in 
mmHg is shown above each time interval. (A) Pre-breast cancer-related lymphedema (pre-BCRL) 
patients before surgery. (B) Non-BCRL patients before surgery. (C) Pre-BCRL patients 21 weeks after 
surgery. (D) Non-BCRL patients 21 weeks after surgery. Before surgery (frame A versus B), the pre-BCRL 
fractional counts in ROI1 rose faster than non-BCRL counts over 2.5–10 min (greater dA/dtROI1, see text) 
and reached a higher peak. Also, after Pcuff was lowered below Ppump the pre-BCRL counts in ROI3 rose 
faster than non-BCRL counts (greater dA/dtROI3). At 21 weeks after surgery, transport dynamics in the 
pre-BCRL patients were substantially reduced compared with prior to surgery (frame A versus C), 
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whereas transport dynamics in the non-BCRL patients were not reduced after surgery (frame B versus 
D). BCRL, breast cancer-related lymphedema; ROI, region of interest. 
 
Figure 5. The effect of surgery on 99mTc-Nanocoll accumulation in the ipsilateral upper limb at 21 weeks 
after surgery in pre-BCRL and non-BCRL patients. Means ± SEM, all values x 103. (A) Maximum count in 
region of interest (ROI)1 (forearm; n = 9 pairs for pre-BCRL, 11 pairs for non-BCRL). (B) Rate of rise of 
activity (dA/dt) in ROI1. (C) Rate of rise of activity in ROI3 (axilla). dA/dt was quantified by linear 
regression analysis of plots of mean fractional counts versus time; dA/dtROI1 describes transport rate 
from depot into forearm during the initial trapped lymph phase (2.5–10.0 min); dA/dtROI3 describes 
transport rate beyond the cuff over 20 min after cuff pressure was reduced below lymphatic pump 
pressure. p, comparisons of presurgery with postsurgery (A, paired t-test; B and C, comparison of 
regression slopes). Surgery greatly reduced arm lymphatic transport in the pre-BCRL group, with less 
effect in the non-BCRL group. BCRL, breast cancer-related lymphedema; ROI, region of interest. 
